



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

April 26, 2019

Katherine Anthony
American Oversight
1030 15th Street NW Suite B255
Washington, District of Columbia 20005
Via email: foia@americanoversight.org

Dear Ms. Anthony:

This letter is regarding your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of January 18, 2019, assigned #19-00356-FOIA, for:

1. Records sufficient to identify all employees who entered into a position at the agency as “political appointees” since January 20, 2017, and the title or position of each employee (to the extent that such individuals have held multiple titles or positions since January 20, 2017, identify each title or position). For purposes of this request, please consider any employee in a PAS position, a presidentially-appointed position, a non-career SES position, a Schedule C position, or any administratively-determined position to be a “political appointee.”
2. Records sufficient to identify all career employees who have been detailed into a leadership office or component front office since January 20, 2017; the title or position of each employee while on detail; and each employee’s originating agency or component, and prior title (to the extent that such individuals have held multiple titles or positions since January 20, 2017, identify each title or position).
3. Names and resumes of anyone from the transition teams or beachhead teams who have joined the agency in full-time capacity, either as career, political, or administratively determined positions since January 20, 2017. For the purposes of this request, please include any employee who previously had a temporary or provisional appointment at the agency before January 20, 2017, and took on a permanent appoint after that date.
4. For each individual identified in response to requests 1 to 3:
 - a. The resume provided by the individual to the agency in connection with determining the appropriate salary for the individual, or, if that is not available, a recent resume contained within the agency’s records. We have no objection to the redaction of contact information (addresses, telephone numbers, e-mail addresses) for the employee or references, or to the redaction of past salary information. Employment, education, and professional association information is not exempt and we object to any redactions of such information.
 - b. Any conflicts or ethics waivers or authorizations for the individual, including

authorizations pursuant to 5 C.F.R. § 2635.502.

- c. Records reflecting any recusal determination made or issued for the individual.
- d. Copies of any SF-50 forms for the individual reflecting any change in position or title, including when the employee enters or leaves a position. We have no objection to the redaction of home addresses, telephone numbers, or social security numbers from the SF-50s.

We located 29 pages and one Excel file of responsive records for Items #1-#3 and Item #4a (29 pages and Excel file released in full or in part. After a careful review of these pages, some information was withheld from release pursuant to 5 U.S.C. §552 Exemption (b)(6).

Exemption 6 protects information in personnel and medical files and similar files when disclosure would constitute a clearly unwarranted invasion of personal privacy. The information that has been withheld under Exemption 6 is a home address. We have determined that the individual to whom this information pertains has a substantial privacy interest in withholding it.

No records were located in response to Items #4b-#4d.

Program staff inform me that personnel actions for Redfield, Campbell, and McGowan [see responsive spread sheet] were processed by the Department of Health and Human Services (HHS). We are therefore referring your request to HHS for their search and direct response to you regarding those individuals. Should you have any questions about their handling of your request, you may contact them directly:


Department of Health and Human Services (HHS)
Freedom of Information Officer
Hubert H. Humphrey Building, Room 729H
200 Independence Avenue, SW
Washington, D.C. 20201
Email: FOIARequest@hhs.gov
Phone: 202-690-7453
Fax: 202-690-8320

No fees are assessed for this request.

You may contact our FOIA Public Liaison at 770-488-6277 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows:
Office of Government Information
Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal by writing to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, Suite 729H, Washington, D.C. 20201. Please mark both your appeal letter and envelope "FOIA Appeal." Your appeal must be postmarked or electronically transmitted by July 25, 2019.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized, cursive script.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

cc: HHS FOIA Officer

Enclosures

19-00356-FOIA

CURRICULUM VITAE

BRENDA CODY FITZGERALD, M.D.

BUSINESS ADDRESS

Georgia Department of Public Health
2 Peachtree St., 15th Floor
Atlanta, GA 30303
Office: 404.657.2703
Email: brenda.fitzgerald@dph.ga.gov

EDUCATION

| | | |
|------|------|---|
| M.D. | 1977 | Emory University School of Medicine, Atlanta, Georgia |
| B.S. | 1972 | Georgia State University, Atlanta, Georgia |

POSTGRADUATE TRAINING

| | |
|-------------|---|
| 1977 – 1981 | Internship and Residency: Obstetrics and Gynecology Emory University Affiliated Hospitals Grady Memorial Hospital Atlanta, Georgia |
|-------------|---|

FACULTY APPOINTMENTS

| | |
|----------------|--|
| 2017 – Present | Affiliated Professor Rollins School of Public Health of Emory University Office of Applied Public Health |
| 1995 – 1999 | Assistant Clinical Professor Emory University School of Medicine Department of Obstetrics/Gynecology |

CERTIFICATIONS

| | |
|----------------|---|
| 1985 – Current | American College Obstetrics and Gynecology Board Certification |
|----------------|---|

LICENSURE

1980 – Current Georgia Medical License

PROFESSIONAL EXPERIENCE

2011 – Current Commissioner, Georgia Department of Public Health

2011 Director, Division of Public Health, Georgia Department of Community Health

2006 – 2011 Gynecologist, Private Practice
Carrollton, Georgia

2001 – 2005 Gynecologist, Tanner Gynecology
Villa Rica, Georgia

1995 – 1999 Director, Emory Executive Women's Health
Assistant Clinical Professor, Emory University School of Medicine
Atlanta, Georgia

1994 – 1995 President, Georgia Obstetric and Gynecological Society

1985 – 1993 Gynecologist, Tanner Medical Center
Carrollton, Georgia

MILITARY/GOVERNMENT SERVICE

United States Air Force, Major

Reserves

1974 – 1981

Active Duty

1981 – 1984 Wurtsmith Air Force Strategic Air Command (SAC) Base
Oscoda, Michigan

1984 – 1985 Andrews Air Force Base
Maryland

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Association of State and Territorial Health Officials

Georgia Obstetric and Gynecological Society

Beta Chi Chapter of Delta Omega (Honorary Member)

CONSULTANTSHIP

1998 – 2000 Health Care Policy Advisor, Senator Paul Coverdell of Georgia

1994 – 1998 Health Care Policy Advisor, House Speaker Newt Gingrich of Georgia

OTHER ACTIVITIES

2004 – Current Senior Fellow, Georgia Public Policy Foundation

2016 – 2017 Board of Director's President Elect, Association of State and Territorial Health Officials

2014 – 2016 Board of Director's Secretary/Treasurer, Association of State and Territorial Health Officials

2014 – 2015 Board of Advisors, Atlanta Speech School

2010 – 2011 Board of Directors, Rotary Club of Carrollton

2004 – 2010 Chairman, Board of Directors, Georgia Public Policy Foundation

2003 – 2010 Member, Military Academy Selections Committee U.S. Senator Saxby Chambliss

2003 – 2008 Board of Trustees, University of West Georgia Foundation

2003 – 2008 Board of Directors, Voices for Georgia's Children

1998 – 2004 Board of Directors, Advanced Academy of West Georgia

1997 – 2004 7th District Representative, Georgia State School Board

1994 – 2000 Member, Military Academy Selections Committee U.S. Senator Paul Coverdell

| | |
|-------------|--|
| 1998 | Founding Member, Board of Directors, Paul Coverdell Leadership Institute |
| 1995 | Visiting Fellow, Heritage Foundation |
| 1990 – 1993 | Board of Directors, Goodwill Industries, Carrollton, Georgia |
| 1991 – 1992 | Board of Directors, Rotary Club of Carrollton |
| 1991 | Vice President, League of Women Voters, Carrollton, Georgia |
| 1989 | Program Chair, Leadership Georgia |
| 1990 – 2000 | Board of Directors, Partnership for Excellence in Education |

CAPT NANCY MESSONNIER, M.D.
Medical Category, PHS # 65846
March 2014

Personal

Home Address: (b)(6)
Business Address: Centers for Disease Control and Prevention
1600 Clifton Road
Atlanta, GA 30333
E-mail NAR5@CDC.GOV
Previous name: Nancy E. Rosenstein

Education

1988-1992: University of Chicago, School of Medicine, M.D.
1983-1987: University of Pennsylvania, College of Arts and Science, B.A.
1979-1983: Lower Moreland High School

Work Experience

4/16-present Director, National Center for Immunization and Respiratory Diseases (NCIRD)

- NCIRD is responsible for supporting national programs for the prevention, control or eventual eradication of serious life-threatening vaccine-preventable diseases, and domestic and international programs aimed at detection, response, and prevention of respiratory threats.
- NCIRD activities include developing, promoting, and evaluating immunization strategies to improve immunization delivery and sustain high immunization coverage levels; working with state, territory and large city grantees on administration of the Vaccines for Children program and implementation of immunization programs that protect individuals and the public from the diseases that vaccines prevent. NCIRD provides scientific and program leadership for influenza and other respiratory threats as well as antimicrobial use in the community and provides laboratory leadership and support for global polio eradication and other global vaccine-preventable and respiratory diseases activities.

10/14-4/2016 Deputy Director, National Center for Immunization and Respiratory Diseases (NCIRD)

- NCIRD is responsible for supporting national programs for the prevention, control or eventual eradication of serious life-threatening vaccine-preventable diseases, and domestic and international programs aimed at detection, response, and prevention of respiratory threats.
- NCIRD activities include developing, promoting, and evaluating immunization strategies to improve immunization delivery and sustain high immunization coverage levels; working with state, territory and large city grantees on administration of the Vaccines for Children program and implementation of immunization programs that protect individuals

and the public from the diseases that vaccines prevent. NCIRD provides scientific and program leadership for influenza and other respiratory threats as well as antimicrobial use in the community and provides laboratory leadership and support for global polio eradication and other global vaccine-preventable and respiratory diseases activities.

- Provide leadership and guidance over the Program Offices, including Science, Laboratory Science, Policy, Communication, Advisory Committee on Immunization Practice, and Global Health Security.

6/14-7/14 Incident Commander, Anthrax Laboratory Exposure

4/14 – 9/14 Interim Director, Office of Advanced Molecular Detection (AMD), National Center for Emerging and Zoonotic Diseases (NCEZID)

- Provides overall leadership and direction for CDC's new FY2014 \$30million Advanced Molecular Detection Program.
- As the first director, provided overall leadership and direction, focused on unlocking the promise of technology to protect Americans from microbial threats and infectious disease outbreaks; developed and implemented governance; developed evaluation metrics; enhanced coordination in the 4 Centers undertaking activities and with outside partners; doubled number of programs with Next Generation Sequencing capability; expanded biological high performance computing environment, and access to high-speed networking; Used AMD data to inform outbreak investigations and responses including - MERS-CoV, Ebola, Enterovirus D68 and Listeria; hired 5 new office staff; deployed new website; developed and implemented plan for FY15 project funding.

9/13-4/14 Acting Deputy Center Director, Center for Surveillance, Epidemiology, and Laboratory Services (CSELS); O6- supervisory billet

- The primary mission of CSELS is to provide scientific service, expertise, skills, and tools in support of CDC's national efforts to promote health; prevent disease, injury and disability; and prepare for emerging health threats.
- CSELS is constituted by 4 divisions: Division of Health Informatics and Surveillance, Division of Laboratory Programs, Standards and Services, Division of Epidemiology, Analysis, and Library Services, and Division of Scientific Education and Professional Development as well as *Morbidity and Mortality Weekly Report (MMWR)* and CDC's *Vital Sign*.
- Deputy Director advises and assists the Director with strategies and operations of a newly reorganized center including the implementation of scientific functions and long term quality improvement strategies.
- Provide leadership and guidance over the Program Offices with a focus on the re-organization transition process and standing up the new center, including implementation of scientific functions and long term quality improvement strategies. Major initiatives launched included: improving the availability and

timeliness of public health surveillance data for CDC programs and state and local health departments; optimizing the use of Epi-info including during the ongoing ebola outbreak; and increasing the use and impact of MMWR in public health decision making such as through a new mobile app.

- 1/13 – 9/13 Acting Director, Division of Global Health Protection (DGHP), Center for Global Health, CDC; O6- supervisory billet
- Tasked with reorganizing two divisions into a single division. The direction of the proposal will be to create a new division to integrate CGH programs that promote strong global health systems, train and build capacity in the global public health workforce, and enhance health security around the world
 - The new Division of Global Health Protection (DGHP) has a total budget of over \$131 million and a staff of approximately 280 employees (78 of whom are assigned internationally), and with an additional 42 unfilled positions. DGHP builds public health capacity in countries and international settings to improve the health and well-being of people around the world by preventing disease, disability and death from communicable and non-communicable diseases. DGHP helps to ensure global health security by protecting the health of Americans and populations around the world through supporting the implementation of the International Health Regulations (IHR), establishing FETP programs and global disease detection centers, detecting emerging health threats, supporting the development of national public health institutions, advancing noncommunicable disease prevention and control and by preparing for and responding to public health emergencies.
- 5/07-1/13 Chief, Meningitis and Vaccine Preventable Disease Branch (MVPDB) Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, CDC O6-supervisory billet
- Duties included strategic oversight, program planning, scientific direction, and management of 95 staff and an annual budget of approximately \$15 million
 - Develop domestic and international public health policy for vaccination against meningococcal disease, *Haemophilus influenzae* serotype b, anthrax, pertussis, diphtheria and tetanus
 - Leadership role as technical expert in CDC's Advisory committee on Immunization Practices for meningococcal disease, pertussis, diphtheria, tetanus, anthrax, and *Haemophilus influenzae*
 - World expert on bacterial meningitis, Co-director of World Health Organization Collaborating Center for Bacterial Meningitis, Steering committee for development of meningococcal conjugate vaccines to eliminate epidemics in Africa

- 5/12-9/13 Co-Lead, Anthrax Management Team
- Coordinated an agency-wide process to coordinate, integrate, prioritize and improve engagement and visibility of issues relating to anthrax preparedness
 - Coordinate anthrax activities on the following: communications, environmental microbiology, epidemiology and surveillance, food and water safety, healthcare delivery, laboratory, medical countermeasures, vaccines and worker safety
- 1/11-1/2013 Co-lead, Anthrax Management Team Vaccine Working Group
- Coordination of a portfolio of activities related to anthrax vaccine
 - Priorities have included priorities for vaccination during an event, vaccine tracking, vaccine safety, and studies to evaluate anthrax vaccines
- 06/05 -5/2007 Chief, Meningitis and Special Pathogens Branch (MSPB)
Division of Bacterial and Mycotic Diseases, NCID; 06-supervisory billet
- Organized into programs on 1) bacterial meningitis and other vaccine preventable diseases of childhood; 2) bacterial zoonoses and non-tuberculous mycobacterium; and 3) evaluation of unexplained deaths and critical illnesses.
 - Strategies and research on integrated infectious disease surveillance and response in the African Region.
 - Development, evaluation, and introduction of vaccines and therapeutics for prevention and treatment of anthrax and meningococcal disease.
 - 95 staff, an annual budget of \$25 million, direct supervision of 12 staff.
- 06/02 -05/05 Chief, Epidemiology Unit, Meningitis and Special Pathogens Branch (MSPB)
Division of Bacterial and Mycotic Diseases, NCID, CDC; 06-supervisory billet
- Direct supervision of 18 staff.
- 10/01-02/02: Anthrax Special Response - detail
- Supervised a team of 10 EIS Officers in the field investigation of the first identified bioterrorism related case of *Bacillus anthracis* in the United States, Florida, 2001. Made critical contributions in the field in Washington, DC, as well as in evaluation of the overall epidemiology of the outbreak
 - Led the evaluation of antimicrobial post-exposure prophylaxis for *B. anthracis* among 10,000 individuals exposed to *B. anthracis*, an unprecedented use of antibiotics, including adverse events, adherence and efficacy
 - Played a leading role in development and implementation of an Investigational New Drug (IND) Application which enabled 1700 individuals to receive additional antibiotics and anthrax vaccine for post-exposure prophylaxis
 - As Primary Investigator, developed a new protocol for post-exposure prophylaxis with antibiotics and anthrax vaccine for persons exposed to *B. anthracis* spores in the event of a new attack

- 8/00 -5/02: Chief, Meningitis Unit, Meningitis and Special Pathogens Branch
Division of Bacterial and Mycotic Diseases, NCID, CDC
- Coordinate branch activities on childhood vaccine preventable diseases
 - Facilitate development, formulation, licensure and use of new meningococcal conjugate vaccines for use domestically and internationally
 - Surveillance in the United States for disease due to *Neisseria meningitidis*, *Haemophilus influenzae* and, in collaboration with the National Immunization Program (NIP), *Bordetella pertussis*
 - Evaluation of strategies for control and prevention of meningococcal disease epidemics in Africa
- 7/97-7/00: Staff Epidemiologist, Meningitis and Special Pathogens Branch, Division of
Bacterial and Mycotic Diseases, NCID
- Facilitate development, formulation, licensure and use of new meningococcal conjugate vaccines for the prevention of meningococcal disease domestically and internationally through provision of a sound scientific basis for their use, and communication with key partners in public health, regulatory agencies, academics and industry
 - Surveillance for disease due to *Neisseria meningitidis* (meningococcal disease) and *Haemophilus influenzae* in the United States
 - Evaluation of current strategies for control and prevention of meningococcal disease epidemics in Africa
- 7/95-6/97: Epidemic Intelligence Officer, Centers for Disease Control and Prevention
Childhood and Respiratory Disease Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Disease (NCID)
- 7/92-6/95: Internal Medicine Resident, University of Pennsylvania, Philadelphia, PA
- 1986/8: Research technician, Department of Neurology, University of Pennsylvania
School of Medicine (full-time 1978/8)

Licensure & Certification

- 1996: American Board of Internal Medicine
(recertified in 2005)
- 1993: State of Pennsylvania Medical Licensure

Committees

Pan American Health Organization (PAHO), Technical Advisory Group (TAG) on vaccines,

7/2017-

National Center for Infectious Diseases Representative to the CDC Commissioned Corps Award Board, 2008 - 2011

Member of the WHO International Health Regulations (IHR 2005) Roster of Experts as an expert in acute neurological syndrome or meningococcal disease, 2008 - 2013

Meningitis Vaccine Project Expert Panel, 2005- 2013

Consultant to the Radiological Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration, 2000-2006

Honors and Awards

PHS

| | |
|------------|--|
| 6/12/2016 | Outstanding Unit Citation for enabling the unprecedented use of an investigational serogroup B meningococcal vaccine to control outbreaks of serogroup B meningococcal disease at two universities. |
| 6/7/2016 | Presidential Unit Citation for Ebola response |
| 2/17/2016 | Outstanding Unit Citation for excellence response to national outbreak of severe respiratory illness by overcoming significant epidemiologic, laboratory, and communication challenges |
| 11/25/2014 | Outstanding Unit Citation for superior performance in the investigation of two state-wide epidemics of pertussis |
| 11/29/2012 | Unit Commendation for National Park Service CDC Zoonotic Team |
| 10/27/2010 | Unit Commendation for effective response to an outbreak of W135 meningococcal disease in the Upper East Region of Ghana |
| 8/9/2010 | Outstanding Unit Citation in recognition of leading the Department of Health and Human Services' prolonged response to the 2009 influenza pandemic |
| 4/15/2010 | Outstanding Unit Citation for the Meningococcal Antimicrobial Resistance Team for response to the emergence of ciprofloxacin-resistant <i>Neisseria meningitidis</i> in North America |
| 4/29/2009 | Outstanding Unit Citation for the Pertussis Outbreak Response Team in recognition of exemplary work in assisting state and local health departments in multiple pertussis outbreaks which lead to national recommendations for pertussis testing |
| 4/29/2009 | Outstanding Unit Citation for the Hib Initiation for exceptional service in preventing childhood pneumonia and meningitis by increasing adoption of Hib vaccines in developing countries |
| 12/16/2008 | Outstanding Unit Citation for the Meningitis Team in recognition designing hands-on laboratory training courses in Brazil, Burkina Faso, India, and China to increase global meningitis disease surveillance |
| 6/19/2008 | Unit Commendation for outstanding service on the Awards Board and support and contributions to the PHS awards process |
| 2/23/2007 | Unit Commendation for outstanding teamwork, scientific & community interaction in the investigation of an inhalational anthrax case |
| 1/12/2006 | Outstanding Service Medal for outstanding leadership to improve control and prevention of meningococcal disease in the U.S. and Africa |
| 10/27/2005 | Unit Commendation for effectively collaborating with state and local health agencies in the assessment and response to an inadvertent |

| | |
|-----------------|---|
| | laboratory exposure to <i>B. anthracis</i> that occurred in California in June 2004 |
| 3/2003-7/2003 | Outstanding Unit Citation for exemplary teamwork and scientific excellence in the investigation and control of SARS during the acute public health response |
| 1/2002 – 7/2002 | Outstanding Unit Citation for extraordinary team contributions in responding to the serogroup W135 meningococcal disease epidemic that caused illness in 13,000 persons in Burkina Faso |
| 9/2001-3/2002 | Outstanding Unit Citation for outstanding service to the people of the United States in responding to terrorist attacks |
| 10/2001-1/2002 | The Crisis Response Service Award for participation in the World Trade Center and Anthrax Responses |
| 10/97-3/2001 | Commendation Medal for evaluation of the risk of meningococcal disease in college students and development of strategies for vaccination |
| 7/1998-9/1998 | Outstanding Unit Citation for the Leptospirosis Response Team |
| 7/1998-6/1999 | Achievement Medal for meningococcal disease surveillance |
| 7/1997-7/1998 | Commendation Medal for outstanding contributions to improve prevention of meningococcal disease in the United States and Africa, USPHS |
| 1/1998-12/1998 | Foreign Duty Service Ribbon, USPHS |
| 1/1998 | Bicentennial Unit Commendation, USPHS |

NON-PHS

| | |
|------------|---|
| 3/2014 | Charles C. Shepard Science Award for Prevention and Control --CDC's highest award for scientific excellence; Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data" (Lancet Infect Dis 12(10): 757-764) |
| 3/2011 | The Philip R Horne Award for unparalleled scientific contribution and leadership in advancing the mission of NICHD and the prevention and control of vaccine-preventable diseases, and for exceptional mentorship and staff development. |
| 3/2009 | 2009 Federal Executive Board's Excellence In Action, Outstanding Team Award, Anthrax Vaccine Research Program |
| 1/2008 | Outstanding Team Performance, OPHS Honor Award, Healthy People 2010 Midcourse Review Team |
| 11/27/2007 | Army Achievement Medal |
| 6/2005 | James H. Nakano Citation for Outstanding paper in Epidemiology and Assessment published in 2003: SARS surveillance during Emergency Public Health Response, United States, March-July 2003 |
| 7/2004 | Secretary's award for distinguished service for The SARS and monkeypox public health response teams |
| 6/2004 | National Center for Infectious Diseases Honor Award Certificate |
| 6/2003 | James H. Nakano Citation for Outstanding paper in Epidemiology and Assessment published in 2002: Investigation of bioterrorism-related anthrax, United States 2001: epidemiologic findings. |

| | |
|--------|---|
| 8/2002 | Certificate of Appreciation. In appreciation of participation and support as a mentor and teacher with the James A. Ferguson Emerging Infectious Diseases Fellowship Program. |
| 6/2002 | CDC/ATSDR Group Honor Award for Contributions to Health and Safety: Anthrax efficacy, adverse events and adherence team for extraordinary effort in monitoring adverse events in the first 10,000 people given prophylactic antibiotics for potential exposure to <i>Bacillus anthracis</i> |
| 6/2002 | CDC/ATSDR Group Honor Award for Anthrax Bioterrorism Investigations Team for leadership and scientific expertise that resulted in the successful investigations and response to anthrax outbreaks at five principal sites |
| 6/2002 | CDC/ATSDR Group Honor Award for Florida and North Carolina Anthrax Investigation Teams for extraordinary team contributions in the successful response to the anthrax investigations in Florida and North Carolina |
| 6/2002 | National Center for Infectious Diseases Honor Award Certificate |
| 6/2002 | James H. Nakano Citation for outstanding scientific paper published in 2001: Risk factors for meningococcal disease in college students |
| 6/2002 | James H. Nakano Citation for outstanding scientific paper published in 2001: Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by <i>Neisseria meningitidis</i> serogroup C |
| 2002 | Certificate of Appreciation from Federal Emergency Management Agency, New York State Emergency Management office |
| 9/2000 | National Immunization Program Certificate of Appreciation in recognition of outstanding contributions to improve prevention of meningococcal disease in the United States and Africa |
| 9/2000 | National Immunization Program Certificate of Appreciation in recognition of outbreak investigation of Leptospirosis among athletes from 44 different states who participated in triathlons in Illinois and Wisconsin |
| 5/1999 | Secretary's Award for Distinguished Service, Group Award, Leptospirosis Triathlon Investigation (DHHS) |
| 5/1998 | Secretary's Award for Distinguished Service, Group Award, Emerging Infections Programs, Active Bacterial Core Surveillance Project (DHHS) |
| 5/1998 | Honor Student Commendation, Basic Project Officer's Course |
| 4/1998 | Alex D. Langmuir Prize Manuscript Nomination (CDC): Opportunities for Prevention of Perinatal Group B Streptococcal Disease |
| 1997 | Alex D. Langmuir Prize Manuscript Nomination (CDC): Efficacy of Meningococcal Vaccine and Barriers to Vaccination |
| 1992 | Alpha Omega Alpha Honor Society |
| 1987 | Magna Cum Laude from the University of Pennsylvania |

Publications (Journal articles, peer reviewed):

102. Meyer SA, Kambou JL, Cohn A, Goodson JL, Flannery B, Medah I, Messonnier N, Novak R, Diomande F, Djingarey MH, Clark TA, Yamcogo I, Fall A, Wannemuehler K. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization. *Vaccine*. 2015; 1492-8.
101. Acosta AM, DeBolt C, Tasslimi A, Lewis M, Stewart LK, Misegades LK, Messonnier NE, Clark TA, Martin SW, Patel M. Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic. *Pediatr*. 2015;2014-3358.
100. Wang X, Shutt KA, Vuong JT, Cohn A, MacNeil J, Schmink S, Plikaytis B, Messonnier NE, Harrison LH, Clark TA, Mayer LW. Changes in the population structure of invasive *Neisseria meningitidis* in the United States after quadrivalent meningococcal conjugate vaccine licensure. *J Infect Dis*. 2015 Jan 2. pii: jiu842.
99. Meningococcal Carriage Among Georgia and Maryland High School Students. Harrison LH, Shutt KA, Arnold KE, Stern EJ, Pondo T, Kiehlbauch JA, Myers RA, Hollick RA, Schmink S, Vello M, Stephens DS, Messonnier NE, Mayer LW, Clark TA. *J Infect Dis*. 2014.
98. Patel M, Romero-Steiner S, Broderick MP, Thomas CG, Plikaytis BD, Schmidt DS, Johnson SE, Milton A, Carlone GM, Clark TA, Messonnier NE, Cohn AC, Faix DJ. Persistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel. *Vaccine* 2014.
97. MacNeil JR, Medah I, Koussoubé D, Novak RT, Cohn AC, Diomandé FV, Yelbeogo D, Kambou JL, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Hatcher C, Vuong J, Mayer LW, Djingarey MH, Clark TA, Messonnier NE. *Neisseria meningitidis* Serogroup W. Burkina Faso 2012. *Emerg Infect Dis* 2014; 20 (3).
96. Ali A, Jafri RZ, Messonnier N, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta Z, Abramson J. Global practices of meningococcal vaccine use and impact on invasive disease. *Pathog Glob Health*. 2014;108(1):11-20.
95. Wright JG, Plikaytis BD, Rose CE, Parker SC, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Semeneva VA, Li H, Schiffer J, Dababneh H, Martin SK, Martin SW, Marano N, Messonnier NE, Quinn CP. Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial. *Vaccine* 2013.
94. Wiringa AE, Shutt KA, Marsh JW, Cohn AC, Messonnier NE, Zansky SM, Petit S, Farley MM, Gershman K, Lynfield R, Reingold A, Schaffner W, Thompson J, Brown ST.

- Lee BY, Harrison LH Geotemporal analysis of *Neisseria meningitidis* clones in the United States: 2000-2005. PLoS One. 2013 Dec 12;8(12):
93. Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison M, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML. Prevalence and molecular characterization of pertactin-deficient *Bordetella pertussis* in the US. Clin Vacc Immunol 2014; 21:119-25.
92. Jafri, RZ, Ali, A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermom F, Klugman KP, Ramsay M, Sow S, Zhujun S, Bhutta ZA, Abramsom J. Global epidemiology of invasive meningococcal disease. Pop Health Metr 2013; 11:17.
91. Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomandé FV, Medah I, Jackson ML. Identifying optimal vaccination strategies for serogroup A *Neisseria meningitidis* conjugate vaccine in the African meningitis belt. PLoS One. 2013;8.
90. Mandal S, Wu HM, Macneil JR, Machesky K, Garcia J, Plikaytis BD, Quinn K, King L, Schmink SE, Wang X, Mayer I.W, Clark TA, Gaskell JR, Messonnier NE, Diorio M, Cohn AC. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the US; Clin Infect Dis. 2013.
89. Tartof SY, Lewis M, Kenyon C, White K, Osborn A, Liko J, Zell E, Martin S, Messonnier NE, Clark TA, Skoff TH. Waning Immunity to Pertussis Following 5 Doses of DTaP; Pediatrics. 2013;131(4):e1047-52.
88. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SA; Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010; JAMA 2012
87. Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré I, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA. Impact of the Serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity; Clin Infect Dis 2012
86. Misegades LK, Martin SW, Messonnier NE, Clark TA; Estimating the effectiveness of acellular pertussis vaccines. Clin Infect Dis. 2012 Nov;55(10):1432-3.
85. Adjemian J, Weber IB, McQuiston J, Griffith KS, Mead PS, Nicholson W, Roche A, Schriefer M, Fischer M, Kosoy O, Laven JJ, Stoddard RA, Hoffmaster AR, Smith J, Bui D, Wilkins PP, Jones JL, Gupton PN, Quinn CP, Messonnier N, Higgins C, Wong D; Zoonotic Infections Among Employees from Great Smoky Mountains and Rocky Mountain National Parks, 2008-2009; Vector Borne Zoonotic Dis 2012.

84. Briere EC, Jackson M, Shah SG, Cohn AC, Anderson RD, MacNeil JR, Coronado FM, Mayer LW, Clark TA, and Messonnier NE; *Haemophilus influenzae* Type b disease and vaccine booster dose deferral. United States, 1998–2009; *Pediatrics* 2012;130:1–7.
83. Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébèogo SR, Clark TA; *Lancet Infect Dis*. 2012.
82. Anderson R, Wang X, Briere EC, Katz LS, Cohn AC, Clark TA, Messonnier NE, Mayer LW. *Haemophilus haemolyticus* isolates causing clinical disease.; *J Clin Microbiol* 2012;50(7):2462-5.
81. Pawloski LC, Kirkland KB, Baughman AL, Martin MD, Talbot EA, Messonnier NE, Tondella ML; Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection? *Clin Vaccine Immunol*. 2012;19(6):875-80.
80. Clark TA, Messonnier NE, Hadler SC; Pertussis control: time for something new? *Trends Microbiol*. 2012 May;20(5):211-3.
79. Krauland MG, Dunning Hotopp JC, Riley DR, Daugherty SC, Marsh JW, Messonnier NE, Mayer LW, Tettelin H, Harrison LH; Whole genome sequencing to investigate the emergence of clonal complex 23 *Neisseria meningitidis* serogroup Y disease in the United States; *PLoS One*. 2012;7(4):e35699.
78. Jackson M, Rose CE, Cohn A, Coronado F, Clark TA, Wenger JD, Bulkow L, Bruce MG, Messonnier NE, and Hennessy TW; Modeling insights into *Haemophilus influenzae* type b disease, transmission, and vaccine programs; *Emerg Inf Dis* 2012;18: 13–20.
77. Skoff TH, Cohn AC, Clark TA, Messonnier NE, Martin SW; Early Impact of the US Tdap vaccination program on pertussis trends; *Arch Pediatr Adolesc Med*. 2012 Apr;166(4):344–9.
76. Mandal S, Tatti KM, Woods-Stout D, Cassidy PK, Faulkner AL, Griffith MM, Jackson ML, Pawloski LC, Wagner B, Barnes M, Cohn AC, Gershman KA, Messonnier NE, Clark TA, Tondella ML, Martin SW; Pertussis pseudo-outbreak linked to specimens contaminated by *Bordetella pertussis* DNA from clinic surfaces.; *Pediatrics*. 2012 Feb;129(2):e424–30.
75. Wang X, Theodore MJ, Muir R, Trujillo-Lopez E, du Plessis M, Wolter N, Baughman AL, Hatcher C, Vuong J, Lott L, von Gottberg A, Sacchi C, McDonald JM, Messonnier NE, Mayer LW; Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens; *J Clin Microbiol*. 2012 Mar;50(3):702–8.

74. Kapasi A, Meade BD, Plikaytis B, Pawloski L, Martin MD, Yoder S, Rock MT, Coddens S, Haezebroeck V, Fievet-Groyné F, Bixler G, Jones C, Hildreth S, Edwards KM, Messonnier NE, Tondella ML. Comparative Study of Different Sources of Pertussis Toxin (PT) as Coating Antigens in IgG Anti-PT ELISAs. Clin Vaccine Immunol 2011.
73. Macneil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, Gershman K, Harrison LH, Lynfield R, Petit S, Reingold A, Schaffner W, Thomas A, Coronado F, Zell ER, Mayer LW, Clark TA, Messonnier NE. Current epidemiology and trends in invasive *Haemophilus influenzae* disease--United States, 1989-2008. Clin Infect Dis 2011;53:1230-6.
72. Stockley A, Cohn A, Dorell C, Hariri S, Yankey D, Messonnier N, Wortley P. Adolescent vaccination coverage levels in the United States: 2006-2009. Pediatrics 2011;128:
71. Thomas JD, Jackson ML, Sharma D, Mair R, Bach MC, Castillo D, Ejigiri OG, Satola S, Cohn AC, Jerris R, Jain S, Farley MM, Mayer LW, Messonnier NE. *Haemophilus influenzae* type b carriage among young children in metropolitan Atlanta in the context of vaccine shortage and booster dose deferral. Clin Vaccine Immunol. 2011;18:2178.
70. Lingappa JR, Dumitrescu L, Zimmer SM, Lynfield R, McNicholl JM, Messonnier NE, Whitney CG, Crawford DC. Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease. PLoS One. 2011;6(8):e23413.
69. Thigpen MC, Whitney CG, Messonnier NE, Zell ER, Lynfield R, Hadler JL, Harrison LH, Farley MM, Reingold A, Bennett NM, Craig AS, Schaffner W, Thomas A, Lewis MM, Seallan E, Schuchat A; Emerging Infections Programs Network. Bacterial meningitis in the United States, 1998-2007. N Engl J Med. 2011 May 26;364(21):2016-25.
68. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, Macneil JR, Schmink S, Muzzi A, Bambini S, Rappuoli R, Pizza M, Murphy E, Hoiseh SK, Jansen KY, Anderson AS, Harrison LH, Clark TA, Messonnier NE, Mayer LH. Prevalence and genetic diversity of candidate vaccine antigens among invasive *Neisseria meningitidis* isolates in the United States. Vaccine 2011;29:4739-44.
67. Dolan Thomas J, Hatcher CP, Satterfield DA, Theodore MJ, Bach MC, Linscott, KB, Zhao X, Wang X, Mair R, Schmink S, Arnold KE, Stephens DS, Harrison LH, Hollick RA, Andrade AI, Lamaro-Cardoso J, DeLemos AP, Gritzfeld J, Gordon S, Soysal A, Bakir M, Sharma D, Jain S, Satola SW, Messonnier NE, Mayer LW: sod-C based real-time PCR for detection of *Neisseria meningitidis*. PLoS One 2011;6:e19361.
66. MacNeil JR, Cohn AC, Zell ER, Schmink S, Miller E, Clark T, Messonnier NE; for the Active Bacterial Core surveillance (ABCs) Team and MeningNet Surveillance Partners.

Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate Vaccine. *Pediatr Infect Dis J*. 2011;30:451-5.

65. Wang X, Mair R, Hatcher C, Theodore MJ, Edmond K, Wu HM, Harcourt BH, Carvalho Mda G, Pimenta F, Nymadawa P, Altantsetseg D, Kirsch M, Satola SW, Cohn A, Messonnier NE, Mayer LW. Detection of bacterial pathogens in Mongolia meningitis surveillance with a new real-time PCR assay to detect *Haemophilus influenzae*. *Int J Med Microbiol*. 2011;301(4):303-9.
64. Kristiansen PA, Diomandé F, Wei SC, Ouédraogo R, Sangaré L, Sanou I, Kandolo D, Kaboré P, Clark TA, Ouédraogo AS, Absatou KB, Ouédraogo CD, Hassan-King M, Thomas JD, Hatcher C, Djingarey M, Messonnier N, Préziosi MP, LaForce M, Caugant DA. Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine. *Clin Vaccine Immunol*. 2011; 18(3):435-43.
63. Somda ZC, Perry HN, Messonnier NR, Djingarey MH, Ki SO, Meltzer MI. Modeling the cost-effectiveness of the integrated disease surveillance and response (IDSR) system: meningitis in Burkina Faso. *PLoS One*. 2010; 28;5(9).
62. Harrison LH, Shutt KA, Schmink SE, Marsh JW, Harcourt BH, Wang X, Whitney AM, Stephens DS, Cohn AA, Messonnier NE, Mayer LW. Population structure and capsular switching of invasive *Neisseria meningitidis* isolates in the pre-meningococcal conjugate vaccine era — United States, 2000-5. *J Infect Dis* 2010;201:1208-1224.
61. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, Craig AS, Farley M, Gershman K, Petit S, Lynfield R, Reingold A, Schaffner W, Shutt KA, Zell ER, Mayer LW, Clark T, Stephens D, Messonnier NE. Changes in *Neisseria meningitidis* disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease. *Clin Infect Dis* 2010 ;50:184-91.
60. Cho BH, Clark TA, Messonnier NE, Ortega-Sanchez IR, Weintraub E, Messonnier ML. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach. *Vaccine* 2010;28:817-22.
59. Whitney AM, Coulson GB, von Gottberg A, Block C, Keller N, Mayer LW, Messonnier NE, Klugman KP. Genotypic comparison of invasive *Neisseria meningitidis* serogroup Y isolates from the United States, South Africa, and Israel, isolated from 1999 through 2002. *J Clin Microbiol*. 2009;47:2787-93.
58. Mutonga DM, Pimentel G, Muindi J, Nzioka C, Mutiso J, Klena JD, Morcos M, Ogaro T, Materu S, Tetteh C, Messonnier NE, Breiman RF, Feikin DR. Epidemiology and risk

- factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. *Am J Trop Med Hyg.* 2009;80:619-24.
57. Wu IHM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, Juni BA, Glennen A, Boxrud DJ, Rainbow J, Schmink S, Mair RD, Theodore MJ, Sander MA, Miller TK, Kruger K, Cohn AC, Clark TA, Messonnier NE, Mayer LW, Lynfield R. Emergence of ciprofloxacin-resistant *Neisseria meningitidis* in North America. *N Engl J Med.* 2009;360:886-92.
56. Somda ZC, Meltzer MI, Perry HN, Messonnier NE, Abdulmumini U, Mehrahtu G, Sacko M, Touré K, Ki SO, Okorosobo T, Alemu W, Sow I. Cost analysis of an integrated disease surveillance and response system: case of Burkina Faso, Eritrea, and Mali. *Cost Eff Resour Alloc.* 2009;7:1.
55. Crawford DC, Zimmer SM, Morin CA, Messonnier NE, Lynfield R, Yi Q, Shephard C, Wong M, Rieder MJ, Livingston RJ, Nickerson DA, Whitney CG, Lingappa J. Integrating host genomics with surveillance for invasive bacterial diseases. *Emerg Infect Dis.* 2008 Jul;14(7):1138-40.
54. Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, Freeman AE, Li H, Mulligan MJ, Parker SD, Babcock J, Keitel W, El Sahly H, Poland GA, Jacobson RM, Keyserling HL, Soroka SD, Fox SP, Stamper JL, McNeil MM, Perkins BA, Messonnier N, Quinn CP, Anthrax Vaccine Research Program Working Group. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. *JAMA.* 2008 Oct 1;300(13):1532-43. Erratum in: *JAMA.* 2008 Nov 19;300(19):2252.
53. Harrison LH, Kreiner CJ, Shutt KA, Messonnier NE, O'Leary M, Stefonek KR, Lin H, Lynfield R, Barrett NL, Arnold KF, Jones TF, Montero JT; Meningococcal High School Study Group. Risk Factors for Meningococcal Disease in Students in Grades 9-12. *Pediatr Infect Dis J.* 2008;27(3):193-9.
52. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE. Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the U.S. *Clin Infect Dis* 2008;46:1-13.
51. Tatti KM, Slade B, Patel M, Messonnier N, Jackson T, Kirkland KB, Talbot EA, Tondella ML. Real-time polymerase chain reaction detection of *Bordetella pertussis* DNA in acellular pertussis vaccines. *Pediatr Infect Dis J.* 2008;27(1):73-4.
50. Schmink S, Watson JT, Coulson GB, Jones RC, Diaz PS, Mayer LW, Wilkins PP, Messonnier N, Gerber SI, Fischer M. Molecular epidemiology of *Neisseria meningitidis*

- isolates from an outbreak of meningococcal disease among men who have sex with men. Chicago. 2003. J Clin Microbiol 2007;
49. Soriano-Gabarro M, Toe L, Tiendrebeogo SR, Nelson CB, Dabal M, Djingarey MH, Plikaytis B, Rosenstein N, WHO Trivalent Vaccine Impact Assessment Group. Effectiveness of a trivalent serogroup A/C/W135 meningococcal polysaccharide vaccine in Burkina Faso, 2003. Vaccine 2007;25 Suppl 1:A92-6.
 48. Walsh JJ, Pesik N, Quinn CP, Urdaneta V, Dykewicz CA, Boyer AE, Guarner J, Wilkins P, Norville KJ, Barr JR, Zaki SR, Patel JB, Reagan SP, Pirkle JL, Treadwell TA, Messonier NR, Rotz LD, Meyer RF, Stephens DS. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis 2007; 44:968–71.
 47. Raghunathan PL, Jones JD, Tiendrebéogo SR, Sanou I, Sangaré I, Kouanda S, Dabal M, Lingani C, Elie CM, Johnson S, Ari M, Martinez J, Chatt J, Sidibe K, Schmink S, Mayer LW, Kondé MK, Djingarey MH, Popovic T, Plikaytis BD, Carlone GM, Rosenstein N, Soriano-Gabarró M. Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso 2001. J Infect Dis 2006;193:607-16.
 46. Brooks R, Woods CWW, Benjamin DK, Rosenstein NE. Increased case-fatality associated with *Neisseria meningitidis* outbreaks compared with sporadic meningococcal disease in the United States, 1994-2002. Clin Infect Dis 2006;43:49-54.
 45. Sejvar JJ, Johnson D, Popovic T, Miller JM, Downes F, Somsel P, Weyant R, Stephens DS, Perkins BA, Rosenstein NE. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Micro 2005; 43(9):4811-4.
 44. Martin SW, Tierney BC, Aranas A, Rosenstein NE, Franzke LH, Apicella L, Marano N, McNeil MM. An overview of adverse events reported by participants in CDC's Anthrax Vaccine and Antimicrobial Availability Program. Pharmacoeconomics and Drug Safety 2005;14:393-401.
 43. Millar EV, O'Brien KL, Watt JP, Lingappa J, Pallipamu R, Rosenstein N, Hu D, Reid R, Santosham M. Epidemiology of invasive *Haemophilus influenzae* type A disease among Navajo and White Mountain Apache children, 1988-2003. Clin Infect Dis 2005;40(6):823-30.
 42. Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005; 115:1220-32.
 41. Dull PM, Adelwahab J, Sacchi CT, Becker M, Noble CA, Barnett GA, Kaiser RM, Mayer LW, Whitney AM, Schmink S, Ajello GW, Dolan-Livengood J, Stephens DS, Cetron

- MS, Popovic T, Rosenstein NE. *Neisseria meningitidis* serogroup W-135 carriage among U.S. travelers to the 2001 Hajj. J Infect Dis 2005;191:33-39.
40. Reissman DB, Whitney EA, Taylor TH Jr, Hayslett JA, Dull PM, Arias I, Ashford DA, Bresnitz EA, Tan C, Rosenstein N, Perkins BA. One-year health assessment of adult survivors of Bacillus anthracis infection. JAMA. 291(16):1994-8. 2004 Apr 28.
39. Schrag SJ, Brooks JT, Van Beneden C, Parashar UD, Griffin PM, Anderson LJ, Beilini WJ, Benson RF, Erdman DD, Klimov A, Ksiazek TG, Peret TC, Talkington DF, Thacker WL, Tondella ML, Sampson JS, Hightower AW, Nordenberg DE, Plikaytis BD, Khan AS, Rosenstein NE, Treadwell TA, Whitney CG, Fiore AE, Durant TM, Perz JF, Wasley A, Feikin D, Herndon JL, Bower WA, Klibourn BW, Levy DA, Coronado VG, Buffington J, Dykewicz CA, Khabbaz RF, Chamberland ME. SARS surveillance during emergency public health response, United States, March-July 2003. Emerg Infect Dis. 10(2):185-94, 2004 Feb.
38. Mothershed EA, Sacchi CT, Whitney AM, Barnett GA, Ajello GW, Schmink S, Mayer LW, Phelan M, Taylor TH Jr, Bernhardt SA, Rosenstein NE, Popovic T. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of *Neisseria meningitidis*. J Clin Microbiol. 42(1):320-8. 2004 Jan.
37. Boras A, Jeren T, Sacchi CT, Schmink S, Bozinovic D, Barsic B, Rosenstein NE, Popovic T, and the Croatian Study Group for Bacterial Meningitis. Establishment of an active laboratory-based surveillance for bacterial meningitis in Croatia and molecular characterization of *Neisseria meningitidis* isolates causing meningococcal disease that were collected in the year 2000, the first year of activity. J Clin Micro 2004; 42:1803-6.
36. Tierney BC, Martin SW, Franzke LH, Marano N, Reissman DB, Louchart RD, Goff JA, Rosenstein NE, Sever JL, McNeil MM. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Clin Infect Dis 2003;37:905-11.
35. Lingappa JR, Al-Rabeah A, Hajjeh R, Mustafa T, Fatani A, Al-Bassam T, Badrkhan A, Turkistani A, Al-Hamdan N, Al-Jelfri M, Mazrou YAL, Perkins BA, Popovic T, Mayer LW, Rosenstein NE. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665-71.
34. Sejvar J, Bancroft E, Winthrop K, Bettinger J, Bajani M, Bragg S, Shutt K, Kaiser R, Marano N, Popovic T, Tappero J, Ashford D, Masciola L, MD, MPH; Duc Vugia, MD; Perkins B, Rosenstein N, and the Eco-Challenge Investigation Team. Outbreak of leptospirosis among athletes participating in "Eco-Challenge-Sabah 2000", Malaysian Borneo. 2000. Emerg Infect Dis 2003; 9:702-7.

33. Shepard CW, Rosenstein NE, Fischer M. Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990 to 1999. *Pediatr Infect Dis J* 2003; 22(5):418-22.
32. LaClaire LJ, Tondella MLC, Beall DS, Nobel CA, Raghunathan PL, Rosenstein NE, Popovic T, and the ABCs Team Members. Identification of *Haemophilus influenzae* serotypes by standard slide agglutination serotyping and PCR-based capsule typing. *J Clin Microbiol* 2003;41:1:393-396.
31. Shepard CW, Soriano-Gabarro M, Zell ER, Hayslett J, Lukacs S, Goldstein S, Factor S, Jones J, Ridzon R, Williams I, Rosenstein N, and the CDC Adverse Events Working Group. Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence. *Emerg Infect Dis* 2002;8:1124-32.
30. Traeger MS, Wiersma ST, Rosenstein NE, Malecki JM, Shepard CW, Raghunathan PL, Pillai SP, Popovic T, Quinn CP, Meyer RM, Zaki SR, Savita Kumar S, Bruce SM, Sejvar JJ, Dull PM, Tierney BC, Jones JD, Perkins BA, and Florida Investigation Team. First Case of Bioterrorism-Related Inhalational Anthrax in the United States, Palm Beach County, Florida, 2001. *Emerg Infect Dis* 2002;8:129-34.
29. Jernigan DB, Raghunathan PL, Bell BB, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarnier J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh W, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL, and the National Anthrax Epidemiologic Investigation Team. Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings. *Emerg Infect Dis* 2002;8:1019-28.
28. Lucher LA, Reeves M, Hennessy, T, Levine OS, Popovic T, Rosenstein N, Parkinson AJ. Reemergence, in Southwestern Alaska, of Invasive *Haemophilus influenzae* Type b Disease Due to Strains Indistinguishable from Those Isolated from Vaccinated Children. *J Infect Dis* 2002;186:958-65.
27. Scott RD, Meltzer ML, Erickson LJ, De Waals P, Rosenstein NE. Vaccinating first-year college students living in dormitories for meningococcal disease. An economic analysis. *Am J Prev Med* 2002; 23:98-105.
26. Kellerman SE, McCombs K, Ray M, Baughman W, Reeves M, Popovic TA, Rosenstein NE, Farley MM, Blake P, Stephens DS and the Georgia Emerging Infections Program. Genotype-Specific carriage of *Neisseria meningitidis* in Georgia Counties with hyper- and hyposporadic Rates of Meningococcal Disease. *J Infect Dis* 2002; 186:40-8.

25. Mayer LW, Reeves MW, Al-Hamdan N, Sacchi CT, Taha M, Ajello GW, Schmink SE, Noble CA, Tondella ML, Whitney AM, Al-Mazrou Y, Al-Jefri M, Mishkhis A, Sabban S, Caugant DA, Lingappa J, Rosenstein NE, and Popovic T. The 2000 outbreak of W135 meningococcal disease: not emergence of a new W135 strain, but clonal expansion within the ET-37 complex. *J Infect Dis* 2002;185:1596-605.
24. Leake JA, Kone ML, Yada AA, Ware A, Dembele P, Rosenstein N, Esteves K, Kawamata J, Heymann DL, Perkins BA. Early Detection and Response to Serogroup A Meningococcal Epidemics in Sub-saharan Africa. *Bull Who* 2002;80:342-9.
23. Lewis R, Nathan N, Communier A, Varaine F, Fermon F, Chahaliier FD, Rosenstein N, Djingarey M, Diarra L, Yada A, Tikhomirov E, Santamaria M, Hardiman M, Leg D. Detection of meningococcal meningitis epidemics in Africa: a new recommendation. [French] *Sante* 2001. 11(4):251-5.
22. Fry AM, Lurie P, Gidley M, Schmink S, Lingappa J, Fischer M, Rosenstein NE. *Haemophilus influenzae* type b illness among Amish children in Pennsylvania: Exploring reasons for persistent disease. *Pediatrics* 2001;108: e60-6.
21. Lingappa JR, Rosenstein N, Zell E, Shutt K, Schuchat A, Perkins B and the Active Bacterial Core surveillance (ABCs) Team of the Emerging Infections Program. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. *Vaccine* 2001;19:4566-75.
20. Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, Roche JC. Emergency of invasive meningococcal disease in persons 15-24 years old in Maryland. *JAMA* 2001;286:694-9.
19. Bruce MG, Rosenstein NE, Capparella J, Shutt KA, Perkins BA, Collins MJ. Risk factors for meningococcal disease in college students. *JAMA* 2001;286:688-93.
18. Krause G, Blackmore C, Wiersma S, Lesneski C, Woods CW, Rosenstein NE, Hopkins RS. Marijuana use and social networks in a community outbreak of meningococcal disease. *Southern Med J* 2001;94:482-5.
17. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. *N Engl J Med* 2001;344: 1378-88.
16. Rosenstein NE, Werner SB, Kao A, Emery K, Rogers D, Vugia E, Reingold A, Talbot R, Plikaytis B, Perkins B, Hajjeh R. Coccidioidomycosis: risk factors for severe pulmonary and disseminated disease. Kern County, California. *Clin Infect Dis* 2001;32:708-15.
15. Popovic T, Schmink S, Rosenstein NE, Ajello GW, Reeves MW, Plikaytis B, Hunter SB, Ribot EM, Boxrud D, Tondella ML, Kim C, Noble C, Mothershed E, Besser J, Perkins

- BA. Evaluation of Pulsed-Field Gel Electrophoresis in Epidemiological Investigations of Meningococcal Disease Outbreaks Caused by *Neisseria meningitidis* Serogroup C. J Clin Microbiol. 2001;39:75-85.
14. Sacchi CT, Whitney AM, Popovic T, Beall DS, Reeves MW, Plikaytis BD, Rosenstein NE, Perkins BA, Tondella MLC, Mayer LW. Diversity and prevalence of PorA types in *Neisseria meningitidis* serogroup B in the United States, 1992-1998. J Infect Dis 2000;182:1169-76.
 13. Tondella MLC, Popovic T, Rosenstein NE, Lake DB, Carlone GM, Mayer LW, Perkins BA. Distribution of *Neisseria meningitidis* serogroup B serotypes and serosubtypes circulating in the United States: identification of predominant antigens for inclusion in multivalent outer membrane protein-based vaccines. J Clin Microbiol 2000;38:3323-8.
 12. Popovic T, Sacchi CT, Reeves MW, Whitney AM, Mayer LW, Noble CA, Ajello GW, Mostashari F, Bendana N, Lingappa J, Hajjeh R, Rosenstein NE. *Neisseria meningitidis* serogroup W135 isolates associated with the ET-37 complex. Emerg Infect Dis 2000;6:428-9.
 11. Woods CW, McRill C, Plikaytis B, Rosenstein N, Mosley D, Boyd D, Perkins BA, England R, Ampel NM, Hajjeh R. Coccidioidomycosis in HIV-infected persons in Arizona, 1994-1997: incidence, risk factors, and prevention. J Infect Dis 2000;181:1428-35.
 10. Rosenstein NE, Stocker SA, Popovic T, Tenover FD, Perkins BA and the Active Bacterial Core Surveillance Team. Antimicrobial resistance of *Neisseria meningitidis* in the United States, 1997. Clin Inf Dis 2000;30:212-3.
 9. Woods CW, Armstrong G, Sackey SO, Tetteh C, Bugri S, Perkins BA, Rosenstein NE. Vaccination against epidemic meningococcal disease in Northern Ghana, 1997. Lancet 2000;355:30-33.
 8. Rosenstein NE, Perkins BA, Stephens D, Lefkowitz L, Cartter M, Moore K, Cieslak P, Shutt K, Popovic T, Schuchat A, Harrison LH, Reingold AL, and the Active Surveillance Team. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999;180:1894-901.
 7. Miller MA, Wenger J, Rosenstein N, Perkins B. Evaluation of meningococcal meningitis control strategies for the meningitis belt in Africa. Peds IDI 1999;18:1051-9.
 6. Tondella ML, Reeves MW, Popovic T, Rosenstein N, Holloway BP, Mayer LW. Cleavase fragment length polymorphism analysis of *Neisseria meningitidis* basic metabolic genes. J Clin Microbiol 1999;37:2402-7.

5. Virata M, Rosenstein NE, Hadler JL, Barrett NL, Tondella ML, Mayer LW, Weyant RS, Hill B, and Perkins BA. Suspected brazilian purpuric fever in a toddler with overwhelming epstein barr virus infection. *Clinical Infectious Diseases* 1998;27:1238-40.
4. Dowell SF, Schwartz B, Phillips WR and the Pediatric URI Consensus Team. Appropriate use of antibiotics for URIs in children: Part II. Cough, Pharyngitis and the common cold. *American Family Physician*;58:1335-42.
3. Rosenstein N, Phillips WR, Gerber MA, Macey SM, Schwartz B, Dowell SF. The common cold--principles of judicious use of antimicrobial agents. *Suppl. Pediatrics* 1998;101:181-84.
2. Rosenstein NE, Levine O, Taylor J, Evans D, Plikaytis BD, Wenger JD, Perkins BA. Efficacy of meningococcal vaccine and barriers to vaccination. *JAMA* 1998;279:435-4394.
1. Rosenstein NE, Schuchat A. Opportunities for prevention of perinatal group b streptococcal disease: A multistate surveillance analysis. *Obstetrics and Gynecology* 1997;90: 901-906.

Selected Publications (chapters, editorials, other)

52. Burns DL, Meade BE, Messonnier NE. Pertussis Resurgence: Perspectives From the Working Group Meeting on Pertussis on the Causes, Possible Paths Forward, and Gaps in Our Knowledge. *J Infect Dis.* (2014) 209 (suppl 1): S32-S35
51. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N; Prevention and control of *Haemophilus influenzae* Type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2013; 63(RR-01):1-14.
50. Meaney-Delman D, Zotti ME, Creanga AA, Misegades LK, Wako E, Treadwell TA, Messonnier NE, Jamieson DJ; Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Workgroup on Anthrax in Pregnant and Postpartum Women. *Emerg Infect Dis.* 2014 Feb;20(2).
49. Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA; Workgroup on Anthrax Clinical Guidelines: Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. *Emerg Infect Dis.* 2014 Feb;20(2)
48. Dakar discussion group on priorities for research on epidemic meningococcal disease in Africa. Altmann D, Aseffa A, Bash M, Basta N, Borrow R, Broome C, Caugant D, Clark T, Collard JM, Djingarey M, Goldblatt D, Greenwood B, Griffiths U, Hajjeh R, Hassan-King M, Hugonnet S, Kimball AM, LaForce M, MacLennan C, Maiden MC, Manigart O, Mayer L, Messonnier N, Moisi J, Moore K, Moto DD, Mueller J, Nascimento M, Obaro S, Ouedraogo R, Page AL, Perea W, Pluschke G, Preziosi MP, Sow S, Stephens D, Stuart J, Thomson M, Tiendrebeogo S, Trape JF, Vernet G. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. *Vaccine.* 2013 Mar;31:1453-7.
47. Misegades LK, Martin SW, Messonnier NE, Clark TA: Estimating the effectiveness of acellular pertussis vaccines. *Clin Infect Dis* 2012;55(10):1432-3.
46. Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez JR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE; Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). *MMWR Recomm Rep* 2013;62(RR-2):1-28.
45. Cohn AC, Messonnier NE. Inching toward a serogroup B meningococcal vaccine for infants; *JAMA* 2012;307(6):614-5
44. Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the

Advisory Committee on Immunization Practices (ACIP), 2009.MMWR Recomm Rep. 2010 Jul 23;59(RR-6):1-30.

43. Tondella ML, Carlone GM, Messonnier N, Quinn CP, Meade BD, Burns DL, Cherry JD, Guiso N, Hewlett EL, Edwards KM, Xing D, Giammanco A, Wirsing von König CH, Han L, Hueston L, Robbins JB, Powell M, Mink CM, Poolman JT, Hildreth SW, Lynn F, Morris A. International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007. Vaccine. 2009 Feb 5;27(6):803-14.
42. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax [conference summary]. Emerg Infect Dis 2008; 14. pii: 07-0969.
41. Fishbein DB, Broder KR, Markowitz L, Messonnier N. New, and some not-so-new, vaccines for adolescents and diseases they prevent. Pediatrics. 2008;121 Suppl 1:S5-14.
40. CDC. Notice to Readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children Aged 2--10 years at increased risk for invasive meningococcal disease. MMWR 2007; 56(48):1265-1266).
39. CDC. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11--18 years with meningococcal conjugate vaccine. MMWR 2007;56:794--5.
38. Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J. 2007; 26:371-6.
37. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report. Vaccine 2006. 24(24):5093-107.
36. Schuchat A, Messonnier NR. From pandemic suspect to the postvaccine era: the Haemophilus influenzae story. Clin Infect Dis. 2007;44(6):817-9.
35. Centers for Disease Control and Prevention. Inhalation anthrax associated with dried animal hides --- Pennsylvania and New York City, 2006. MMWR 2006; 55(10):280-282.
34. Bilukha O, Rosenstein N. Centers for Disease Control and Prevention (Prepared by O. Bilukha and N. Rosenstein). Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005;54(RR7):1-21.

33. Meehan PJ, Rosenstein NE, Gillen M, Meyer RF, Kiefer MJ, Deitchman S, Besser RE, Ehrenberg RL, Edwards KM, Martinez KF. Responding to detection of aerosolized *Bacillus anthracis* by autonomous detection systems in the workplace. *MMWR* 2005; 53(RR-7):1-12.
32. Soriano-Gabarró M, Rosenstein N, LaForce M. A demonstration project to evaluate a serogroup A meningococcal vaccine in Africa. *Journal of Health, Population and Nutrition* 2004;22:275-85.
31. Zell ER, Shepard C, Rosenstein NE. Follow-up of persons impacted by bioterrorism: respondents and nonrespondents. 2003 Proceedings of the Section on Survey Research Methods of the American Statistical Association. ASA: Alexandria, VA. 4717-4721
30. Rosenstein NE, Feikin DR. Vaccines against bacterial meningitis. In: Scheld WM, Whitley RJ, Mara CM, eds. *Infections of the Central Nervous System*. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:899-920.
29. Meehan PJ, Rosenstein NE, Gillen M, Meyer RF, Kiefer MJ, Deitchman S, Besser RE, Ehrenberg RL, Edwards KM, Martinez KF. Responding to detection of aerosolized *Bacillus anthracis* by autonomous detection systems in the workplace. *Morbidity & MMWR*. 53(RR-7):1-12. 2004 Jun 4.
28. Raghunathan PL, Bernhardt SA, Rosenstein N. Opportunities for Control of Meningococcal Disease in the United States. *Ann Rev Int Med* 2004; 55:333-53.
27. Soriano-Gabarró M, Rosenstein NE, Pinner RW, Stephens DS. Epidemic bacterial meningitis. In: D. Armstrong and J. Cohen, editors. *Infectious Diseases*, 2nd ed; Mosby 2004;6:1539-44.
26. Rosenstein NE, Perkins BA. Commentary: Group A meningococcal meningitis in sub-saharan Africa. The case for mass followed by routine vaccination with polysaccharide vaccines. *Bull WHO* 2003; 81:752-3.
25. Schaffner W, Rosenstein NE, Stephens DS, Harrison LH, Kaczmarski EB, LaForce FM. The changing global epidemiology of meningococcal disease with an emphasis on future prevention. Summary of a roundtable discussion addressing strategies for controlling and preventing global incidence of meningococcal disease. A publication of the National Foundation for Infectious Diseases. Eds. Aug 2002.
24. Soriano-Gabarro M, Stuart JM, Rosenstein NE. Vaccines for the prevention of meningococcal disease in children. *Seminars in Pediatr Infect Dis* 2002; 13:182-9.

23. Centers for Disease Control and Prevention. Update: adverse events associated with anthrax prophylaxis among postal employees B New Jersey, New York, and the District of Columbia Metropolitan Area, 2001. MMWR 50:1051-4.
22. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. In Vaccine recommendations: challenges and controversies. P. Gardner and G. Peter, Editors. Infect Dis Clin North Am 2001;15: 155-169.
21. Rosenstein NE. Opportunities to decrease mortality and long-term sequelae associated with meningococcal disease in Africa. Intl J Epi 2001; 30:1447-8.
20. Dull P, Rosenstein N. Meningococcal disease and vaccines. Pediatric Annals 2001. 30(6):358-61.
19. Centers for Disease Control and Prevention. Exposure to patients with meningococcal disease on aircrafts -- United States, 1999-2001. MMWR 2001;50:487-9.
18. Rosenstein NE. Global surveillance for meningococcal disease. In: Pollard A and Maiden M, editors. Meningococcal disease: methods and protocols (Methods in molecular medicine; 67). New Jersey: Human press; 2001. p.333-9.
17. Pollard AJ, Scheifele D, Rosenstein NE. Epidemiology of meningococcal disease in North America. In: Pollard A and Maiden M, editors. Meningococcal disease: methods and protocols (Methods in molecular medicine; 67). New Jersey: Human press; 2001. p.341-56.
16. Rosenstein NE and Perkins BA. Update on *Haemophilus influenzae* serotype b and meningococcal vaccines. Peds Inf Dis Clin North America 2000;47:337-352.
15. Centers for Disease Control and Prevention. Human ingestion of bacillus anthracis-contaminated meatBMinnnesota, August 2000. MMWR 2000;49:813-6.
14. Centers for Disease Control and Prevention. Public health dispatch: Outbreak of acute febrile illness among participants in EcoChallenge Sabah 2000 Malaysia. 2000. MMWR 2000;49:816-7.
13. Centers for Disease Control and Prevention (NE Rosenstein, author). Meningococcal disease and college students: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;RR7:11-20.
12. Centers for Disease Control and Prevention (NE Rosenstein, author). Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;RR7:1-10.

11. Centers for Disease Control and Prevention. Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia B United States. MMWR 2000;49:345-6.
10. Martone WJ, Schaffner W, Collins M, Harrison LH, Perkins BA, Peter G, Rosenstein NE. The changing epidemiology of meningococcal disease in the U.S. with an emphasis on college health issues. A summary of a roundtable discussion sponsored by Postgraduate Institute for Medicine. A publication of the National Foundation for Infectious Diseases. Eds. May 1999.
9. Centers for Disease Control and Prevention. Meningococcal Disease -- New England, 1993 - 1998. MMWR 1999; July 30, 1999;48:629-33.
8. Rosenstein NE, Pinner B, Stephens D. Bacterial meningitis in the tropics. In: D. Armstrong and J. Cohen, editors. Infectious Diseases: Mosby 1999;6:20.1-20.4.
7. Centers for Disease Control and Prevention. Progress toward eliminating *Haemophilus influenzae* type B disease among infants and children B United States, 1987-1997. MMWR 1998;47:993-98.
6. Levine O, Wenger J, Perkins BA, Rosenstein NE, Schuchat A. *Haemophilus influenzae* type B infection. Bull WHO 1998;76 (Suppl 2): 131-2.
5. Centers for Disease Control and Prevention. Update: Leptospirosis and unexplained acute febrile illness among athletes participating in triathlons B Illinois and Wisconsin, 1998. MMWR 1998;47:673-6.
4. Centers for Disease Control and Prevention. Outbreaks of group B meningococcal disease -- Florida, 1995 and 1997. MMWR 1998; 47:833-7.
3. Centers for Disease Control and Prevention (NE Rosenstein, author). Decreasing incidence of perinatal group b streptococcal disease -- United States, 1995-1996. MMWR 1997;46(21):473-477.
2. Perkins BA, Broome CV, Rosenstein NE, Schuchat A, Reingold AL. Meningococcal vaccine in sub-Saharan Africa. The Lancet 1997;350:1708.
1. Centers for Disease Control and Prevention (NE Rosenstein, author). Serogroup Y meningococcal disease -- U.S. 1989-1996. MMWR 1996;45(46): 1010-13.

All

| Name First | Name Last | MI | Position Title | Educ Level Descr | Eff Date | NOA Code | NOA Code Desc | Authority |
|------------|------------|---------|--------------------------------|------------------|----------|----------|----------------|-----------|
| Robert | Redfield | RAY | Director, Center For Disease C | Master degree | 5/14/18 | 546 | Conv to SES N | V4L |
| Amanda | Campbell | CAROLIN | Deputy Chief Of Staff | Master degree | 4/29/18 | 570 | Conv to Except | Y7M |
| Robert | Mcgowan | K | Chief Of Staff | Bachelors Degree | 4/6/18 | 546 | Conv to SES N | V4L |
| Brenda | Fitzgerald | C | Director, Cdc - Administrator | Master degree | 7/7/17 | 146 | SES Noncareer | V4L |
| Nancy | Messonnier | ELLEN | Distinguished Consultant | Doctorate degree | 10/1/17 | 170 | Exc Appt | ZLM |
| Nancy | Messonnier | ELLEN | Distinguished Consultant | Doctorate degree | 10/1/17 | 170 | Exc Appt | ZLM |

All

| Authority2 | Authority Desc1 | Authority Desc2 | Position Occup | Position Occup desc | App Type |
|------------|--|------------------|-------------------|---------------------|----------|
| AWM | 5 U.S.C. 3394(a). Non- career. SES noncar. | OPM Form 1652 Da | 3 | SES General | 55 |
| ZLM | SCH C, 213.3301a Agency- unique Schedule | OPM Form 1019 Da | 2 | Excepted | 44 |
| ZLM | 5 U.S.C. 3394(a). Non- career. SES noncar. | OPM Form 1652 Da | 3 | SES General | 55 |
| AWM | 5 U.S.C. 3394(a). Non- career. SES noncar. | OPM Form 1652 da | 3 | SES General | 55 |
| | 42 USC 209f | | 2 | Excepted | 38 |
| | 42 USC 209f | | 2 | Excepted | 38 |

All

| AppType Desc | Grade | GVT Step | pay plan | PayPlan Desc | series | series desc |
|-----------------------|-------|----------|----------|---------------------------|--------|---------------------------|
| NonCareer (SES Perm) | 00 | 00 | ES | Senior Executive Service | 0602 | Medical officer - (0602) |
| Schedule C (Non Perm) | 15 | 01 | GS | General Schedule | 0301 | Miscellaneous administrat |
| NonCareer (SES Perm) | 00 | 00 | ES | Senior Executive Service | 0301 | Miscellaneous administrat |
| NonCareer (SES Perm) | 00 | 00 | ES | Senior Executive Service | 0602 | Medical officer - (0602) |
| Other (Excepted Perm) | 00 | 00 | RF | Distinguished Consultants | 0602 | Medical officer - (0602) |
| Other (Excepted Perm) | 00 | 00 | RF | Distinguished Consultants | 0602 | Medical officer - (0602) |

All

| Manager level |
|-----------------------|
| Supervisor or Manager |
| Supervisor or Manager |
| Supervisor or Manager |
| Supervisor or Manager |
| Supervisor or Manager |
| Supervisor or Manager |